Mizuho analyst Ann Hynes raised the firm’s price target on Iqvia (IQV) to $225 from $190 and keeps an Outperform rating on the shares. The company’s booking trends were stable in the quarter, much better than feared, the analyst tells investors in a research note. The firm says that when coupled with improved cancelation rates and an improvement in trial delays, there is increased earnings visibility for 2026.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IQV:
- Positive Growth Outlook for IQVIA Holdings Amid Increased RFP Activity and Strong TAS Performance
- Iqvia price target raised to $220 from $180 at Evercore ISI
- Iqvia price target raised to $225 from $185 at UBS
- Iqvia price target raised to $235 from $209 at Truist
- Iqvia price target raised to $196 from $159 at Baird